rPeptide 产品列表和技术资料（八）

百度网盘下载

rPeptide是美国一家生物化学研发公司，主要产品涉及领域为老年性痴呆症与帕金森综合症研究使用的重组蛋白，重组多肽，抗体以及试剂等等，另外还提供一系列外包服务，从分子生物学，蛋白表达与蛋白纯化到13C与15N 统一标记蛋白与多肽。同时， rPeptide 技术平台可解决可溶性多肽/蛋白（例如：β-淀粉样蛋白、廋蛋白、前胰岛素）在大肠杆菌中表达等历史性难题。

以下是该公司部分代表产品：

Antibodies（抗体）

Peptides（多肽类）

Proteins（蛋白质）

Neurodegenerative related compounds（神经退行性相关化合物）

Coronavirus research tools（冠状病毒研究工具）

Kits(试剂盒）

Preformed fibrils（预成型的纤维）

rPeptide 产品列表

Neurodegenerative Related Compounds

货号	名称	规格	产品描述
N-3001-1	CTPB	5.0mg	A selective activator of p300 HAT (histone acetyltransferase) selective over PCAF (p300 CPB-associated factor) 1,2. Promotes survival and neurite growth in a cellular model (SH-SY5Y cells) of Parkinson’s 3. Protects cells from death induced by the neurotoxin 5-hydroxydopamine 3.
N-3001-2	CTPB	25.0mg
N-3018-1	DAPT	5.0mg	Inhibitor of gamma-secretase (IC50 in human primary neurons = 115 nM for total amyloid beta or 200 nM for Amyloid Beta 42 specifically) 1. Oral administration of DAPT has been shown to reduce levels of Amyloid Beta in brain extract, cerebrospinal fluid and plasma from mice and rats 2,3. DAPT blocks Notch signaling which promotes neuronal differentiation of precursor cells 4. Enhances iPS cells without oncogenes KLF4 and CMYC 5. Cell permeable.
N-3018-2	DAPT	25.0mg
N-3026-1	Diazoxide	100.0mg	Activates ATP-dependent K+ channels 1 via inducing translocation of PKC-epsilon from the cytosol to the mitochondria 2. Hyperglycemic agent. Induces powerful protective effects against cardiac ischemia via multiple mechanisms 3. Stimulates mitochondrial ATP synthase activity conferring cardioprotection in a streptozotocin-induced acute diabetes model 4. Prevents alterations in memory and synaptic plasticity induced by Amyloid-Beta 5.
N-3026-2	Diazoxide	500.0mg
N-3034-1	Edaravone	1gm	An antioxidant free radical scavenger. Displays protective effects in cerebral ischemia 1. Prevents MPTP-induced neurotoxicity in the substantia nigra but not the striatum 2. Clinically useful agent for treatment of amyotrophic lateral sclerosis 3. Alleviates cisplatin-induced neurobehavioral deficits by modulating oxidative stress in rat hippo-campus 4. Prevents cardiac dysfunction by suppressing oxidative stress in diabetic rats 5.
N-3034-2	Edaravone	5gm
N-3025-1	Fingolimod	5.0mg	An analog of sphingosine which, when taken up into cells, is phosphorylated and acts as an agonist at sphingosine-1-phosphate receptors (S1P1/3) 1. Potently inhibits regulatory T cell proliferation in vitro and in vivo 2. Enhances microvascular remodeling via expansion of arterioles and capillary networks 3. Potent immunomodulatory 4. Clinically effective agent for relapsing forms of multiple sclerosis 5.
N-3025-2	Fingolimod	25.0mg
N-3024-1	FK-506	20mg	FK-506 induces immunosuppression by inhibiting T cell proliferation. Inhibits FKBP12 and calcineurin (IC50ca. 1 nM) 1. Reduces neuroinflammation and neuro-degeneration in an alpha-synuclein-based rat model of Parkinson’s disease 2. Increases the rate of axonal regeneration following crush injury in a rat model 3. Cell permeable.
N-3024-2	FK-506	100.0mg
N-3020-1	Imatinib Mesylate	20mg	Tyrosine kinase inhibitor specific for bcr-abl (IC50 = 38 nM) 1, PDGF-R (IC50 = 0.3 μM)1 and c-kit (IC50 = 0.1 μM) 2. It is a clinically useful anti-cancer drug approved for the treatment of chronic myelogenous leukemia, gastrointestinal stromal tumors as well as several other cancers 3. Lowers Amyloid Beta levels by indirect inhibition of gamma-secretase without inhibiting gamma-secretase processing of Notch1 4.
N-3020-2	Imatinib Mesylate	100.0mg
N-3017-1	IOS-1	10.0mg	Antagonist of macrophage migration inhibitory factor (MIF, a pro-inflammatory cytokine). Displays anti-inflammatory activity. Increases survival in severe sepsis 1. Inhibits airway remodeling in mouse asthma model 2. Blocks MIF-induced autophagy 3. Inhibits experimental autoimmune diabetes in a mouse model, reducing islet antigen-specific proliferative responses and adhesive cell-cell interactions 4. Active in cellular and mouse models. Reverses Amyloid Beta-induced toxicity in mouse and human neuronal cell lines
N-3017-2	IOS-1	50.0mg
N-1539-1	ISRIB	5.0mg	Integrated stress response inhibitor. Potently reverses the effects of initiation factor 2α (eIF2α) phosphorylation, IC50=5 nM 1. Enhances spatial and fear-associated learning in mice and enhances cognitive function 1,2. Mechanism of action involves activation of eiF2β 3. Suppresses ER stress-induced inflammatory gene expression 4. Potently attenuates amyloid β-induced neuronal cell death (12.5-25 nM) with no effect on amyloid β production 5. Reverses hippocampal-dependent cognitive deficits induced by traumatic brain injury in two different injury mouse models
N-1539-2	ISRIB	25.0mg
N-3010-1	ISX9	5.0 mg	Promotes neurogenesis in vivo enhancing the proliferation and differentiation of hippocampal subgranular zone neuroblasts and enhances memory 1. Induces robust neuronal differentiation in adult neural stem cells 2. Increases insulin production by pancreatic Beta cells 3. Blocks malignant astrocyte proliferation, downregulates their astrocyte character, induces reentry into the cell cycle and upregulates neuronal gene expression 4. Induces sensory neurons from neuroepithelial stem cells
N-3010-2	ISX9	25.0 mg
N-1197-1	IU1	10.0 mg	Selective inhibitor of Usp14 (IC50<4 µM). Enhances proteasome activity and substrate proteolysis 1,2. Inhibits Dengue virus replication 3. In prion-infected CAD5 cells activation of the ubiquitin proteasome system by IU1 is sufficient to induce clearance of polyubiquitinated substrates and reduce misfolded prion protein load 4. Attenuates ischemia/reperfusion-induced neuronal injury in a mouse model 5. Cell permeable.
N-1197-2	IU1	50.0 mg
N-3005-1	LM11A-31 2HCI	5.0 mg	A nonpeptide neurotrophic factor receptor p75 (p75NTR) agonist which promotes survival signaling in neurotrophin-responsive cells 1. Promotes functional recovery in a mouse model of spinal contusion injury 2. Protects neurogenesis after traumatic brain injury 3. Reverses cholinergic neurite dystrophy in Alzheimer’s disease mouse models 4. Stabilizes neuronal calcium, preserves mitochondrial movement and protects against HIV-associated neuropathogenesis 5. Orally active and blood-brain barrier permeant.
N-3005-2	LM11A-31 2HCI	25.0 mg
N-3006-1	LM22A-4	10.0 mg	Small molecule BDNF mimetic displaying neurotrophic activity. Partial agonist at TrkB and activates TrkB signaling. In in vitro models of neurodegenerative disease, it prevented neuronal degeneration with equal efficacy to that of BDNF. After in vivo administration, it caused hippocampal and striatal TrkB activation in mice and improved motor learning after traumatic brain injury in rats 1. Improves respiratory function in a mouse model of Rett syndrome
N-3006-2	LM22A-4	50.0 mg
N-3013-1	Minocyline HCI	50.0 mg	Displays antiapoptotic, anti-inflammatory 1 activity. Prevents neuropathic pain in a rat sciatic nerve injury model 1. Reduces MMP-9 activity 2. Attenuates disease severity in mouse models of multiple sclerosis 3. Displays neuroprotective activity 4. May be effective in methotrexate-induced lung fibrosis 5. Orally active and brain penetrant.
N-3013-2	Minocyline HCI	250.0 mg	Displays antiapoptotic, anti-inflammatory 1 activity. Prevents neuropathic pain in a rat sciatic nerve injury model 1. Reduces MMP-9 activity 2. Attenuates disease severity in mouse models of multiple sclerosis 3. Displays neuroprotective activity 4. May be effective in methotrexate-induced lung fibrosis 5. Orally active and brain penetrant.
N-1363-1	Mitoquinone	5.0 mg	A mitochondria-targeted antioxidant. Displays cardio and neuroprotective effects 1. Displays beneficial effects in mouse models of Alzheimer’s disease 2. Protects pancreatic β-cells against oxidative stress and improves insulin secretion 3. Cell permeable.
N-1363-2	Mitoquinone	25.0 mg
N-3028-1	Montelukast Sodium	50.0 mg	Potent, selective CysLT1 receptor (leukotriene D4) antagonist (Ki = 0.18 nM) 1,2. Displays anti-inflammatory and anti-asthmatic effects. Clinically useful agent for treatment of chronic asthma 3. Attenuates chronic brain injury after focal cerebral ischemia in rodent models 4. Decreases blood brain barrier dysfunction in mouse models 5. Blockade of GPR17 by montelukast elevates neural stem and progenitor proliferation
N-3028-2	Montelukast Sodium	250.0 mg
N-3014-1	Neurodazine	5.0 mg	Induces neurogenesis of pluripotent P19 cells producing physiologically active neurons which respond to glutamate 1. Compared to retinoic acid, neurodazine is more selective due to its unique ability to suppress astrocyte differentiation. Induces neuronal differentiation in neuroblastoma and fibroblast cells by activating the Wnt signaling pathway
N-3014-2	Neurodazine	25.0 mg
N-3015-1	Neuropathiazol	5.0 mg	Induces neuronal differentiation of multipotent hippocampal neural progenitor cells. It is more potent and selective compared to retinoic acid. Selectively suppresses astrogliogenesis when induced by LIF, BMP2 and FBS. Enhances maturation of NPC-derived neurons.
N-3015-2	Neuropathiazol	25.0 mg
N-3004-1	P7C3	5.0 mg	P7C3 exerts proneurogenic activity by protecting newborn neurons from apoptosis. Prolonged administration to aged rats impedes neuronal death and preserves cognitive capacity 1. Delays disease progression in G93A-SOD2 mutant mouse model of amyotrophic lateral 2. Blocks MPTP-mediated cell death of dopaminergic neurons in the substantia nigra of adult mice, a model of Parkinson disease 3. Restores hippocampal neurogenesis in a mouse model of Down Syndrome 4. The mechanism of action involves activation of nicotinamide phosphoribosyltransferase (NAMPT) with concomitant increase of intracellular levels of NAD 5. Active in vivo.
N-3004-2	P7C3	25.0 mg
N-2856-1	Pinacidil	10.0 mg	Activates ATP-dependent potassium channels 1,2. Induces vascular relaxation and antihypertensive effects 3. Prevents the loss of mitochondrial inner membrane potential, protecting cerebellar granule neurons from apoptosis induced by oxidative stress 4. Displays protective effects in Parkinson’s disease models 5 and cerebral ischemia-reperfusion
N-2856-2	Pinacidil	50.0 mg
N-3011-1	Prostratin	1.0 mg	A terpenoid, non-tumorigenic PKC activator isolated from Pimelia prostrata 1. Induces differentiation of human myeloid leukemia cells and potentiates differentiation by chemotherapeutic agents 3. Induces reactivation of latent HIV 4. Exerts a proliferative effect on neural progenitor cells in vitro and in vivo
N-3011-2	Prostratin	5.0 mg
N-3022-1	Rapamycin	20.0 mg	Potent immunosuppressant. The rapamycin-FKBP12 complex binds to and inhibits mTOR 1. Inhibits IL-2-induced activation of p70 S6 kinase 2. Extends lifespan of mice 3. Induces autophagy in a variety of cell lines
N-3022-2	Rapamycin	100.0 mg
N-3019-1	Resveratrol	100.0 mg	Naturally occurring phenolic antioxidant. Displays antitumor and antiplatelet effects 1. Activates SIRT1 and increases longevity in yeast 2. Ameliorates ageing-related phenotypes by inhibition of cAMP phosphodiesterases 3. Stimulates increased expression of transthyretin which binds Amyloid Beta peptide and prevents its aggregation and toxicity 4. Attenuates Amyloid Beta induced neurotoxicity by induction of autophagy
N-3019-2	Resveratrol	500.0 mg
N-1461-1	Salirasib	5.0mg	Displaces active Ras protein from the plasma membrane inhibiting its activity, IC50=10-15 µM 1. Enhances autophagy in a variety of cell lines 2. Protects against HIV-1-induced accumulation of Aβ in human brain microvascular endothelial cells 3. Displays antiinflammatory activity, inhibiting the release of PGD2 and TNFα from mast cells
N-1461-2	Salirasib	25.0 mg
N-3016-1	SB-225022	5.0 mg	Potent and selective CXCR2 receptor antagonist (IC50 = 22 nM). Displays >150-fold selectivity over CXCR1 receptors 1. Induces apoptosis in both wild-type and p53-deficient ovarian cancer cells (OVCA) via p53 activation and by inducing mitotic catastrophe 2. Blocks IL-8-mediated cellular effects such as oxidative stress-induced cellular senescence 3 and neutrophil chemotaxis 1. Inhibits HIV replication in lymphocytes and macrophages 4. Inhibits endothelial activation and leukocyte recruitment to cerebral microvessels during neuroinflammation
N-3016-2	SB-225022	25.0 mg
N-3008-1	Tianeptine	10.0 mg	Selective enhancer of serotonin uptake in the brain with no effect on noradrenalin or dopamine uptake. Clinically useful antidepressant 2. Displays neuroprotective effects against hypoxia in cell culture and against the deleterious effects of cytokines in vivo 3. Induces mTORC1 activation in rat hippocampal neurons and increases dendritic outgrowth, spine density and synaptic proteins 4. Attenuates LPS-evoked inflammatory activation of microglial cells in culture
N-3008-2	Tianeptine	50.0 mg
N-3007-1	Tolcapone	10.0 mg	Catechol O-methyltransferase inhibitor (COMT), inhibiting both brain and peripheral enzymes 1. Potent inhibitor of alpha-synuclein and beta-amyloid oligomerization and fibrillogenesis protecting against extracellular toxicity 2. Binds to transthyretin (TTR) with high affinity (21 to 58 nM) and inhibits TTR aggregation in human plasma and prevents TTR-induced cytotoxicity in vitro. Stabilizes TTR in mice and humans in vivo 3. Inhibits O-methylation of exogenous polyphenols such as EGCG 4. Cell permeable. Orally bioavailable.
N-3007-2	Tolcapone	50.0 mg
N-3029-1	TRO 19622	5.0 mg	Neuroregenerative and neuroprotective agent acting at components of the mitochondrial permeability transition pore (MPTP) 1. Rescues motor neurons from axotomy-induced cell death and promotes nerve regeneration following sciatic nerve crush in mice. Reduces ROS and NLRP3 inflammasome activation in a mouse model of intracerebral hemorrhage 2. Inhibits MPTP opening and protects neurons from apoptosis 3. Induces oligodendrocyte maturation in culture and promotes myelin regeneration in vivo in a rodent model
N-3029-2	TRO 19622	25.0 mg
N-3021-1	Vorinostat	50.0 mg	Potent and selective histone deacetylase inhibitor 1. Induces apoptosis in a variety of tumor cell lines (IC50 = 3-8 μM) 2. Synergizes with kinase inhibitors to kill CNS tumor cells 3. Prevents diabetes in a mouse model by immunoregulation and -cell protection 4. Induces neuronal differentiation in DKFZ-EP1NS cells, a cell line which displays stem cell features such as self-renewal capacity 5. Cell permeable.
N-3021-2	Vorinostat	250.0 mg
N-3023-1	Zileuton	10.0 mg	Reversible inhibitor of 5-Lipoxygenase (IC50 = 500 nM in RBL-1 cells and 300 nM rat PMNLs)1. It also inhibited leukotriene B4 biosynthesis (IC50’s = 400nM rat PMNL, 400nM human PMNL) 1. Zileuton suppressed prostaglandin biosynthesis via interference with arachidonic acid release in macrophages independent of 5-LO inhibition (IC50 = 13 μM PGE2 inhibition in LPS-stimulated whole blood) 2. Restores memory impairments and reverses amyloid and tau pathology in an Alzheimer’s mouse model
N-3023-2	Zileuton	50.0 mg
N-3033-1	Zolmitriptan	10.0 mg	Potent and selective serotonin 5HT 1B/1D agonist (Ki=0.63 and 5.01 nM for 5HT 1D and 1B respectively. Displays proven efficacy for the treatment of migraine. Inhibits neurogenic inflammation and pain during electrical stimulation in human skin. Induces nerve growth, integration and function in transplanted heterologous organs in regenerative medicine.
N-3033-2	Zolmitriptan	50.0 mg